Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Dermatologic 1

Conditions

Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1

Interventions

Cyclophosphamide 39Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 30Busulfan 26Filgrastim 24Cyclosporine 24Mycophenolic Acid 22Antilymphocyte Serum 22Radiotherapy 20Melphalan 16Whole-Body Irradiation 15Tacrolimus 14Methylprednisolone 14Methotrexate 13Cord Blood Stem Cell Transplantation 12Etoposide 10sargramostim 5Thiotepa 5Temozolomide 5Sirolimus 5Rituximab 5Bevacizumab 5aldesleukin 4Therapeutics 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4Carmustine 4pembrolizumab 3Vincristine 3Topotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × iratumumab × Sarcoma × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡